DTZ has been liaising with ASX in relation to a potential...

DTZ has been liaising with ASX in relation to a potential announcement regarding the
ability of its fluoresecent-based technology to detect viruses in the field, in real time,
using individual DNA. DTZ has filed a Patent application on methods and conjugates for
rapid and real-time detection of viruses, and is now undertaking further testing of the
application of this technology in relation to COVID-19. To enable further development
of this unique DTZ technology, a letter of intent for a Technology Collaboration
Agreement has been signed with Brazilian genetic and health company FullDNA to
provide insights on protein architecture and analysis of trial results. In addition, to
facilitate clinical testing on confirmed COVID-19 patients, a Letter of Intent has been
signed with the highly regarded Sheba Medical Centre in Israel.
In addition, DTZ has also recently signed a pilot agreement with Zohar-Dalia Cooperative
Agricultural Association Ltd for use of ValidotzTM markers in disinfectant materials to
verify surface coverage for signs of any virus, including COVID-19 (“Pilot”. DTZ wil
receive a nominal fee for the Pilot. Zohar Dalia is Israel's largest, most advanced
manufacturer, supplier, and developer of detergent intermediates and cleaning